Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:NLTX NASDAQ:OGI NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$8.36-4.9%$6.69$3.76▼$46.80$51.12M2.77213,631 shs60,315 shsNLTXNeoleukin Therapeutics$21.43-2.4%$18.28$2.03▼$14.36$201.40M1.1150,104 shs113,400 shsOGIOrganigram Global$1.45-1.4%$1.34$0.85▼$2.08$194.21M1.36666,252 shs769,488 shsPROKProKidney$4.54-12.4%$1.05$0.46▼$7.13$1.33B1.263.29 million shs17.60 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%+5.16%+4.11%+104.90%-34.41%NLTXNeoleukin Therapeutics+0.80%+6.67%+2.44%+94.82%-44.42%OGIOrganigram Global0.00%+2.11%-1.36%+40.78%-8.23%PROKProKidney0.00%+558.93%+406.70%+520.81%+81.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALGSAligos Therapeutics4.0943 of 5 stars3.53.00.04.82.21.70.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOGIOrganigram Global1.1528 of 5 stars0.01.00.00.03.10.02.5PROKProKidney2.663 of 5 stars2.14.00.00.03.04.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 3.00Buy$70.00737.32% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/AOGIOrganigram Global 3.00BuyN/AN/APROKProKidney 2.25Hold$5.3317.47% UpsideCurrent Analyst Ratings BreakdownLatest ALGS, OGI, NLTX, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $9.006/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$3.94M12.96N/AN/A($7.50) per share-1.11NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AOGIOrganigram Global$117.47M1.65N/AN/A$2.07 per share0.70PROKProKidney$80K16,610.73N/AN/A($3.41) per share-1.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$131.21M-$17.51N/AN/AN/A-1,628.75%14.67%7.19%8/5/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AOGIOrganigram Global-$33.39M$0.1014.50N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)PROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest ALGS, OGI, NLTX, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025PROKProKidney-$0.14N/AN/AN/AN/AN/A8/5/2025Q2 2025ALGSAligos Therapeutics-$2.35N/AN/AN/A$0.43 millionN/A5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 million5/6/2025Q1 2025ALGSAligos Therapeutics-$2.80-$2.11+$0.69-$2.11$0.33 million$0.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A7.567.56NLTXNeoleukin TherapeuticsN/A15.3315.33OGIOrganigram GlobalN/A3.421.90PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%NLTXNeoleukin Therapeutics52.37%OGIOrganigram Global34.63%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics4.80%NLTXNeoleukin Therapeutics1.58%OGIOrganigram Global0.09%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.11 million5.82 millionNo DataNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataOGIOrganigram Global860133.94 million133.82 millionOptionablePROKProKidney3292.70 million171.26 millionOptionableALGS, OGI, NLTX, and PROK HeadlinesRecent News About These CompaniesProKidney's (PROK) "Buy" Rating Reiterated at CitigroupJuly 12 at 3:51 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Sees Large Volume Increase Following Analyst UpgradeJuly 12 at 2:19 AM | americanbankingnews.comProKidney (PROK) Gets a Sell from Bank of America SecuritiesJuly 11 at 3:51 PM | theglobeandmail.comProKidney (NASDAQ:PROK) Shares Gap Down - Should You Sell?July 11 at 12:06 PM | marketbeat.comProKidney (NASDAQ:PROK) Sees Large Volume Increase After Analyst UpgradeJuly 10 at 10:48 AM | marketbeat.comDarin J. Weber Sells 103,480 Shares of ProKidney Corp. (NASDAQ:PROK) StockJuly 10 at 6:41 AM | insidertrades.comProKidney Shares Soar After Citi Lifts Price Target to $9July 10 at 4:14 AM | msn.comRilparencel De-Risks Phase 3 As ProKidney Enters Price DiscoveryJuly 10 at 4:14 AM | seekingalpha.comProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 103,480 SharesJuly 9, 2025 | marketbeat.comTop Penny Stocks To Add to Your Watchlist - July 9thJuly 9, 2025 | marketbeat.comBiotech Stocks To Follow Today - July 9thJuly 9, 2025 | marketbeat.comPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy StudyJuly 9, 2025 | zacks.comProKidney (NASDAQ:PROK) Given New $9.00 Price Target at CitigroupJuly 9, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Sets New 1-Year High - Here's WhyJuly 9, 2025 | marketbeat.comTrump's latest tariff threats and the impact on markets, ProKidney stock jumps over 500%July 9, 2025 | youtube.comYProKidney: What's Happening With PROK Stock?July 9, 2025 | forbes.comProKidney: Study 'Win' Send Shares Soaring >500% - New Valuation Feels FairJuly 9, 2025 | seekingalpha.comProKidney Corp. Management to Participate in H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 9, 2025 | quiverquant.comQProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual ConferenceJuly 9, 2025 | globenewswire.comDow Tumbles Over 150 Points Amid Trump Tariffs: Investor Sentiment Declines, Fear Index Moves To 'Greed' ZoneJuly 9, 2025 | benzinga.comProkidney produces positive phase II CKD data, thunderous stock surgeJuly 8, 2025 | bioworld.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right NowUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractWhy Occidental's Price Dip Signals a Buying OpportunityBy Jeffrey Neal Johnson | July 3, 2025View Why Occidental's Price Dip Signals a Buying OpportunityALGS, OGI, NLTX, and PROK Company DescriptionsAligos Therapeutics NASDAQ:ALGS$8.36 -0.43 (-4.89%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$9.22 +0.87 (+10.35%) As of 07/11/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Neoleukin Therapeutics NASDAQ:NLTX$21.43 -0.53 (-2.41%) As of 07/11/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Organigram Global NASDAQ:OGI$1.45 -0.02 (-1.36%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.ProKidney NASDAQ:PROK$4.54 -0.64 (-12.36%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.54 0.00 (-0.11%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? 3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Conagra at Rock Bottom: 7% Yield & Turnaround Poised Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
